PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2111556
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2111556
Medical Polyoxymethylene (POM) Market size was valued at US$ 1,400.8 Million in 2025, expanding at a CAGR of 8.8% from 2026 to 2033.
The Medical Polyoxymethylene (POM) industry includes the production and application of polyoxymethylene (POM), a special engineering thermoplastic material with high-performance characteristics such as strength, stiffness, low friction, dimensional stability, and chemical resistance. It is used in the production of precision parts such as drug delivery systems, surgical instruments, diagnostics, connectors, valves, pumps, and medical device housing. The demand in the industry is fueled by the increasing demand for light-weight, durable, and highly precise components for medical devices. Polyoxymethylene allows for close dimensional tolerances and smooth movement of the parts; therefore, it can be used for gear, actuator, and other moving parts of the medical devices.
Medical Polyoxymethylene Market- Market Dynamics
Growing Adoption of Advanced Drug-Delivery Devices
The rising popularity of compact, precise drug-delivery devices presents prospects for medical-grade POM owing to the combination of low-friction, dimensionally stable, fatigue-resistant, and performing material in moving parts. These are especially applicable for auto-injectors, inhalers, insulin delivery systems, infusion devices, and dose control mechanisms where the movement of the component needs to be consistent over several uses. The FDA in its 2024 draft guidance particularly noted that syringes, auto-injectors, on-body injectors, infusion pumps, inhalers, nebulizers, and nasal sprays are the major categories of drug-delivery devices requiring demonstration of delivery performance. In conjunction, specialty-material companies have also been bolstering their engineered polymers portfolio: in 2022, Celanese had completed the US$11 billion acquisition of DuPont's Mobility & Materials business.
The Global Medical Polyoxymethylene Market is segmented on the basis of Product Type, Application, Processing Method, End User, and Region.
Homopolymer POM gives advantages in the form of high crystallinity, stiffness, strength, and dimensional stability; thus, it can be used for precision medical device components subjected to mechanical stress and repetitive movements. In turn, copolymer POM demonstrates superior performance in terms of heat, hydrolysis, and process resistance, which makes it a choice for devices where sterilization and contact with chemicals is required. Selection of product depends on specific design and sterilization methods used. Globally, there are more than 2 billion tonnes of healthcare waste per year, leading to increased importance of durable, light-weighted and reliable polymer components in medical-device production.
Medical device components serve as a wide range of applications including gears, valves, connectors, housings, actuators, etc. There are more and more drug delivery systems with components made of POM that requires constant movements. Surgical tools can utilize POM due to its strength and resistance to wear. There are diagnostic equipment with components made of POM, used in precision mechanisms and fluid handling assemblies, and orthopedic and dental applications with rigid POM materials with low friction properties. According to WHO 15% of healthcare waste is hazardous.
The Medical POM Market has moderate consolidation, with competition based not only on commodity pricing but on medical grade formulation, documentation, process control, and supply assurance. Celanese stands out through the availability of its Hostaform(R) MT series of medical POM resins suitable for complicated drug delivery systems. DuPont/Delrin concentrates on specialized medical grades and improved manufacturing and testing facilities. It also promotes the use of renewable attribute POM grades. Polyplastics engages in application-specific product development. It recently introduced the new range of drug contact and delivery grades of its DURACON(R) POM resins carrying ISO 10993, USP Class VI, FDA DMF/MAF and other certifications. Mitsubishi Engineering-Plastics, KEP, BASF, Ensinger, Rochling, Westlake Plastics, Mitsubishi Chemical, Asahi Kasei, SABIC, Kolon Plastics, and LyondellBasell compete on specialized engineering polymers, custom formulated products, processing technology, and global supply networks. In general, suppliers move toward application engineered resins, regulatory support, sustainability, and cooperation with OEMs rather than just commodity resin sales.
In April 2026, Delrin introduced Delrin(R) ZA (Zero Attributed) at CHINAPLAS 2026, positioning it as the industry's first carbon-neutral acetal. The new material expands Delrin's sustainable POM portfolio while retaining the performance characteristics of acetal homopolymer. The launch demonstrates how leading POM producers are increasingly combining material performance with lower-carbon manufacturing and sustainability requirements.
In February 2025, Polyplastics reported that its medical-grade DURACON(R) POM portfolio was undergoing evaluation by multiple medical-device OEMs following its commercial introduction. The company highlighted particular interest in rotational drug-delivery applications, including insulin pens and pumps, where POM's low friction and dimensional stability can support precise dosing mechanisms.